Top Stories
Neurotech Pharmaceuticals' cell therapy Encelto is the only FDA-approved treatment for macular telangiectasia type 2.
The approval was based on data from the Phase III REPLENISH study, which demonstrated a roughly 41% remission rate for Cosentyx in patients with the inflammatory rheumatic disease.
The success of the TYK2/JAK1 inhibitor in the CLARITY programme for non-infectious uveitis comes shortly after it was approved by the FDA for dermatomyositis.
Deborah Waterhouse, the current CEO of ViiV Healthcare, will assume the role of chief executive and managing director at CSL from Feb. 1 next year.
A marketing application for the invasive aspergillosis indication is expected to be resubmitted to the FDA before year-end.
Conference News
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for...
– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerabilit...
Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple scl...
Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcersSARASOTA, Fla., Oct. 21...
77% of participants remained in care and on long-acting HIV treatment, Cabenuva, with a median treatment duration of 18 monthsAmong individuals switching to Cabenuva, 94% had a last viral load ...
